• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Patient Registry of Spasticity Care World: Data Analysis Based on Physician Experience
Objective The aim of the study was to report physician experience–based “real-world” treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury. Design A prospective, multicenter, international observational registry design was used. Results Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians. Due to the limited usage of abobotulinumtoxinA Dysport and incobotulinumtoxinA Xeomin, data were reported on onabotulinumtoxinA BOTOX only. ...
Source: American Journal of Physical Medicine and Rehabilitation - November 17, 2017 Category: Rehabilitation Tags: Original Research Articles Source Type: research

Dose-Dependent Effects of Abobotulinumtoxina (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study
Conclusions Previous clinical trials have established the clinical efficacy of abobotulinumtoxinA by total dose only. The wide range of abobotulinumtoxinA doses per muscle groups used in this study allowed observation of dose-dependent improvements in spasticity and active movement. This information provides a basis for future abobotulinumtoxinA dosing recommendations for health care professionals based on treatment objectives and quantitative assessment of spasticity and active range of motion at individual joints. Level of Evidence I
Source: PMandR - July 17, 2017 Category: Rehabilitation Source Type: research

Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial
Conclusions The efficacy and safety of abobotulinumtoxinA in subjects previously treated with BoNT-A were consistent with those in the total trial population. Hence, abobotulinumtoxinA is a treatment option in these patients, and no difference in initial dosing appears to be required compared to that in individuals not treated previously. Level of Evidence To be determined.
Source: PMandR - July 6, 2017 Category: Rehabilitation Source Type: research

Dose-Dependent Effects of Abobotulinumtoxina (Dysport ®) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of A Phase 3 Study
Conclusions Previous clinical trials have established the clinical efficacy of abobotulinumtoxinA by total dose only. The wide range of abobotulinumtoxinA doses per muscle groups used in this study allowed observation of dose-dependent improvements in spasticity and active movement. This information provides a basis for future abobotulinumtoxinA dosing recommendations for healthcare professionals based on treatment objectives and quantitative assessment of spasticity and active range of motion at individual joints.
Source: PMandR - June 20, 2017 Category: Rehabilitation Source Type: research

Efficacy and safety of abobotulinumtoxinA (Dysport ®) for the treatment of hemiparesis in adults with upper limb spasticity previously treated with botulinum toxin: sub-analysis from a Phase 3, randomized controlled trial
Conclusions The efficacy and safety of abobotulinumtoxinA in subjects previously treated with BoNT-A were consistent with those in the total trial population. Hence, abobotulinumtoxinA is a treatment option in these patients and no difference in initial dosing appears to be required compared to individuals not treated previously.
Source: PMandR - June 17, 2017 Category: Rehabilitation Source Type: research